Stock Scorecard



Stock Summary for Kezar Life Sciences Inc (KZR) - $7.49 as of 11/20/2024 8:22:18 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for KZR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for KZR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for KZR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for KZR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for KZR (38 out of 90)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for KZR

VistaGen Therapeutics, Inc. ( VTGN ) Reports Q2 Loss, Misses Revenue Estimates 11/8/2024 12:30:00 AM
Anika Therapeutics ( ANIK ) Reports Q3 Loss, Lags Revenue Estimates 10/31/2024 12:25:00 PM
Looking Into Kezar Life Sciences's Recent Short Interest - Kezar Life Sciences ( NASDAQ:KZR ) 10/29/2024 8:15:00 PM
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Kezar Life Sciences ( NASDAQ:KZR ) 10/17/2024 5:37:00 PM
What Makes Kezar Life Sciences ( KZR ) a New Buy Stock 10/15/2024 4:00:00 PM
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Saratoga Investment ( NYSE:SAR ) 10/9/2024 9:32:00 AM
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths - Kezar Life Sciences ( NASDAQ:KZR ) 10/7/2024 12:50:00 PM
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug - Kezar Life Sciences ( NASDAQ:KZR ) 8/14/2024 4:06:00 PM
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond 2/25/2024 8:34:00 PM
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period ( 2019-2032 ) | DelveInsight 11/21/2023 10:01:00 PM

Financial Details for KZR

Company Overview

Ticker KZR
Company Name Kezar Life Sciences Inc
Country USA
Description Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 7.49
Price 4 Years Ago 52.20
Last Day Price Updated 11/20/2024 8:22:18 PM EST
Last Day Volume 106,671
Average Daily Volume 614,231
52-Week High 11.35
52-Week Low 5.20
Last Price to 52 Week Low 44.04%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -58.97
Free Cash Flow Ratio 0.37
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 7.65
Total Cash Per Share 20.34
Book Value Per Share Most Recent Quarter 25.77
Price to Book Ratio 0.36
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 7.78
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 7,296,200
Market Capitalization 54,648,538
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -49.28%
Reported EPS 12 Trailing Months -13.50
Reported EPS Past Year -3.35
Reported EPS Prior Year -1.41
Net Income Twelve Trailing Months -95,778,000
Net Income Past Year -101,870,000
Net Income Prior Year -68,239,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -14.22

Balance Sheet

Total Cash Most Recent Quarter 148,388,000
Total Cash Past Year 201,372,000
Total Cash Prior Year 276,561,000
Net Cash Position Most Recent Quarter 138,126,000
Net Cash Position Past Year 191,303,000
Long Term Debt Past Year 10,069,000
Long Term Debt Prior Year 10,000,000
Total Debt Most Recent Quarter 10,262,000
Equity to Debt Ratio Past Year 0.95
Equity to Debt Ratio Most Recent Quarter 0.93
Total Stockholder Equity Past Year 187,570,000
Total Stockholder Equity Prior Year 269,872,000
Total Stockholder Equity Most Recent Quarter 134,049,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -76,386,000
Free Cash Flow Per Share Twelve Trailing Months -10.47
Free Cash Flow Past Year -83,455,000
Free Cash Flow Prior Year -60,424,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.02
MACD Signal 0.03
20-Day Bollinger Lower Band 4.72
20-Day Bollinger Middle Band 6.62
20-Day Bollinger Upper Band 8.52
Beta 0.22
RSI 51.62
50-Day SMA 7.71
150-Day SMA 47.30
200-Day SMA 53.89

System

Modified 11/19/2024 5:03:24 AM EST